Sonelokimab Emerging Drug Insight and Market Forecast – 2032

Sonelokimab Emerging Drug Insight and Market Forecast – 2032

“Sonelokimab Emerging Drug Insight and Market Forecast – 2032” report provides comprehensive insights about Sonelokimab for Hidradenitis Suppurativa (HS) in the 7MM. A detailed picture of the Sonelokimab for Hidradenitis Suppurativa in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan, for the study period 2019–2032 is provided in this report along with a detailed description of the Sonelokimab for Hidradenitis Suppurativa. The report provides insight about mechanism of action, dosage, and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Sonelokimab market forecast, analysis for Hidradenitis Suppurativa in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Hidradenitis Suppurativa.

Drug Summary

Sonelokimab (M1095) is an investigational ~40 kDa humanized Nanobody consisting of three VHH domains covalently linked by flexible glycine-serine spacers. With two domains, sonelokimab selectively binds with high affinity to IL-17A and IL-17F, thereby inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers. A third central domain binds to human albumin, facilitating further enrichment of sonelokimab at sites of inflammatory edema. The drug is currently in the Phase II stage of development for treating the patients with hidradenitis suppurativa (HS).

Sonelokimab has the potential to elevate patient outcomes due to its ability to inhibit the IL-17A/A, IL-17A/F, and IL-17F/F dimers that drive inflammation in many inflammatory diseases, and its Nanobody characteristics should additionally improve tissue penetration, helping the molecule to target difficult-to-reach inflammatory lesions. Top-line results on the primary endpoint, for the novel IL-17A and IL-17F inhibitor Nanobody sonelokimab, expected mid-2023.

In February 2023, MoonLake Immunotherapeutic announced that it had completed enrollment of the target 210 patients randomized ahead of schedule in its global Phase II clinical trial evaluating sonelokimab in moderate-to-severe hidradenitis suppurativa (HS).

Scope of the Report

The report provides insights into:

A comprehensive product overview including the Sonelokimab description, mechanism of action, dosage and administration, research and development activities in Hidradenitis Suppurativa.

Elaborated details on Sonelokimab regulatory milestones and other development activities have been provided in this report.

The report also highlights the Sonelokimab research and development activity in Hidradenitis Suppurativa in detail across the United States, Europe, and Japan.

The report also covers the patents' information with an expiry timeline around Sonelokimab.

The report contains forecasted sales of Sonelokimab for Hidradenitis Suppurativa till 2032.

Comprehensive coverage of the late-stage emerging therapies for Hidradenitis Suppurativa.

The report also features the SWOT analysis with analyst views for Sonelokimab in Hidradenitis Suppurativa.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals, and access to available databases.

Sonelokimab Analytical Perspective by DelveInsight

In-depth Sonelokimab Market Assessment

This report provides a detailed market assessment of Sonelokimab in Hidradenitis Suppurativa in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2027 to 2032.

Sonelokimab Clinical Assessment

The report provides the clinical trials information of Sonelokimab in Hidradenitis Suppurativa covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

In the coming years, the market scenario for Hidradenitis Suppurativa is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Sonelokimab dominance.

Other emerging products for Hidradenitis Suppurativa are expected to give tough market competition to Sonelokimab and the launch of late-stage emerging therapies in the near future will significantly impact the market.

A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Sonelokimab in Hidradenitis Suppurativa.

Our in-depth analysis of the forecasted sales data from 2027 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Sonelokimab in Hidradenitis Suppurativa.

Key Questions

What is the product type, route of administration, and mechanism of action of Sonelokimab?

What is the clinical trial status of the study related to Sonelokimab in Hidradenitis Suppurativa and study completion date?

What are the key collaborations, mergers and acquisitions, licensing, and other activities related to the Sonelokimab development?

What are the key designations that have been granted to Sonelokimab for Hidradenitis Suppurativa?

What is the forecasted market scenario of Sonelokimab for Hidradenitis Suppurativa?

What are the forecasted sales of Sonelokimab in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?

What are the other emerging products available in Hidradenitis Suppurativa and how are they giving competition to Sonelokimab for Hidradenitis Suppurativa?

Which are the late-stage emerging therapies under development for the treatment of Hidradenitis Suppurativa?